期刊
JOURNAL OF IMMUNOLOGY
卷 192, 期 12, 页码 5451-5458出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1490019
关键词
-
类别
资金
- Intramural NIH HHS [Z01 BC010984-01] Funding Source: Medline
The ability of IL-2 to expand T cells with maintenance of functional activity has been translated into the first reproducible effective human cancer immunotherapies. The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer. The growth of large numbers of tumor-infiltrating lymphocytes with in vitro anti-cancer activity in IL-2 has led to the development of cell transfer therapies that are highly effective in patients with melanoma. The genetic modification of T cells with genes encoding alpha beta TCRs or chimeric Ag receptors and the administration of these cells after expansion in IL-2 have extended effective cell transfer therapy to other cancer types.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据